

# BRITISH JOURNAL OF PHARMACOLOGY

The *British Journal of Pharmacology* welcomes contributions in all fields of experimental pharmacology including neuroscience, biochemical, cellular and molecular pharmacology. The Board of Editors represents a wide range of expertise and ensures that well-presented work is published as promptly as possible, consistent with maintaining the overall quality of the journal.

## *Edited for the British Pharmacological Society by*

**A.T. Birmingham**  
(Chairman)

**R.W. Horton      W.A. Large**  
(Secretaries)

### Editorial Board

P.I. Aaronson *London*  
J.A. Angus *Melbourne, Australia*  
G.W. Bennett *Nottingham*  
T.P. Blackburn *Harlow*  
N.G. Bowery *London*  
W.C. Bowman *Glasgow*  
S.D. Brain *London*  
K.D. Butler *Horsham*  
M. Caulfield *London*  
R. Chess-Williams *Sheffield*  
T. Cocks *Melbourne, Australia*  
S.J. Coker *Liverpool*  
R.A. Coleman *Ware*  
Helen M. Cox *London*  
A.J. Cross *London*  
V. Crunelli *Cardiff*  
T.C. Cunnane *Oxford*  
F. Cunningham *London*  
A. Dickenson *London*  
J.R. Docherty *Dublin*  
A. Dray *London*  
L. Edvinsson *Lund, Sweden*  
G. Edwards *Manchester*  
J.M. Edwardson *Cambridge*  
R.M. Eglen *Palo Alto, USA*  
P.C. Emson *Cambridge*  
A.C. Foster *San Diego, USA*  
J.R. Fozard *Basle, Switzerland*  
Allison D. Fryer *Baltimore, USA*

J.P. Gallagher *Galveston, USA*  
Sheila M. Gardiner *Nottingham*  
C.J. Garland *Bristol*  
A. Gibson *London*  
M.A. Gienbycz *London*  
W.R. Giles *Calgary, Canada*  
R.G. Goldie *Perth, Australia*  
R.J. Griffiths *Connecticut, USA*  
R.W. Gristwood *Cambridge*  
Judith M. Hall *London*  
D.W.P. Hay *Philadelphia, USA*  
P.G. Hellewell *London*  
P.E. Hicks *Edinburgh*  
S.J. Hill *Nottingham*  
K. Hillier *Southampton*  
S.M.O. Hourani *Guildford*  
J.C. Hunter *Palo Alto, USA*  
E.J. Johns *Birmingham*  
R.S.G. Jones *Oxford*  
C.C. Jordan *Ware*  
P.A.T. Kelly *Edinburgh*  
D.A. Kendall *Nottingham*  
C. Kennedy *Glasgow*  
P. Leff *Loughborough*  
A.T. McKnight *Cambridge*  
C.A. Maggi *Florence, Italy*  
Janice M. Marshall *Birmingham*  
G. Martin *Beckenham*  
W. Martin *Glasgow*

A. Mathie *London*  
D.N. Middlemiss *Harlow*  
P.K. Moore *London*  
C.D. Nicholson *Oss, The Netherlands*  
H. Osswald *Tübingen, Germany*  
F.L. Pearce *London*  
J.D. Pearson *London*  
A.G. Renwick *Southampton*  
P.J. Roberts *Bristol*  
G.J. Sanger *Harlow*  
W.C. Sessa *Connecticut, USA*  
P. Sneddon *Glasgow*  
K. Starke *Freiburg, Germany*  
R.J. Summers *Melbourne, Australia*  
P.V. Taberner *Bristol*  
J. Tamargo *Madrid, Spain*  
C. Thiernemann *London*  
M.D. Tricklebank *Basle, Switzerland*  
T.J. Verbeuren *Suresnes, France*  
R.R. Vollmer *Pittsburgh, USA*  
K.J. Watling *Boston, USA*  
A.H. Weston *Manchester*  
J. Westwick *Bath*  
Eileen Winslow *Riom, France*  
E.H.F. Wong *Milan, Italy*  
B. Woodward *Bath*

### Corresponding Editors

P.R. Adams *Stony Brook, U.S.A.*  
C. Bell *Dublin*  
F.E. Bloom *La Jolla, U.S.A.*  
A.L.A. Boura *Newcastle, Australia*  
N.J. Dun *Toledo, U.S.A.*  
R.F. Furchgott *New York, U.S.A.*  
T. Godfraind *Brussels, Belgium*  
S.Z. Langer *Paris, France*

R.J. Miller *Chicago, U.S.A.*  
R.C. Murphy *Denver, U.S.A.*  
E. Muscholl *Mainz, Germany*  
R.A. North *Geneva, Switzerland*  
M. Otsuka *Tokyo, Japan*  
M.J. Rand *Melbourne, Australia*  
S. Rosell *Södertälje, Sweden*  
P. Seeman *Toronto, Canada*

L. Szekeres *Szeged, Hungary*  
B. Uvnäs *Stockholm, Sweden*  
P.A. Van Zwieten *Amsterdam, Netherlands*  
V.M. Varagić *Belgrade, Yugoslavia*  
G. Velo *Verona, Italy*  
Wang Zhen Gang *Beijing, China*  
M.B.H. Youdim *Haifa, Israel*

**Submission of manuscripts:** Manuscripts (two copies) should be sent to The Editorial Office, British Journal of Pharmacology, St. George's Hospital Medical School, Cranmer Terrace, London SW17 0RE.

Authors should consult the Instructions to Authors and the Nomenclature Guidelines for Authors in Vol. 114, 245–255. These Instructions and Guidelines also appear with the journal Index for Volumes 111–113, 1994. A checklist of the essential requirements is summarised in each issue of the journal, or as the last page of the issue.

Whilst every effort is made by the publishers and editorial committee to see that no inaccurate or misleading data, opinion or statement appears in this Journal, they and the *British Pharmacological Society* wish to make it clear that the data and opinions appearing in the articles and advertisements herein are the responsibility of the contributor or advertiser concerned. Accordingly, the *British Pharmacological Society*, the publishers and the editorial committee and their respective employees, officers and agents accept no liability whatsoever for the consequences of any such inaccurate or misleading data, opinion or statement.

**G.H. Allcock, T.D. Warner & J.R. Vane.** Roles of endothelin receptors in the regional and systemic vascular responses to ET-1 in the anaesthetized ganglion-blocked rat: use of selective antagonists **2482**

**J. Waller, S.M. Gardiner, J. Jose & T. Bennett.** Lack of effect of TNF antibodies on the cardiovascular sequelae of lipopolysaccharide infusion in conscious rats **2487**

**O. Piot, J. Betschart, I. Grall, S. Ravard, C. Garret & J.-C. Blanchard.** Comparative behavioural profile of centrally administered tachykinin NK<sub>1</sub>, NK<sub>2</sub> and NK<sub>3</sub> receptor agonists in the guinea-pig **2496**

**H. El-Bizri, M.G. Rigdon & P.B.S. Clarke.** Intraneuronal accumulation and persistence of radiolabel in rat brain following *in vivo* administration of [<sup>3</sup>H]-chlorisondamine **2503**

**K.E. Ellis, R. Mistry, J.P. Boyle & R.A. J. Challiss.** Correlation of cyclic AMP accumulation and relaxant actions of salmeterol and salbutamol in bovine tracheal smooth muscle **2510**

**M. Takeda & H. Lepor.** Nitric oxide synthase in dog urethra: a histochemical and pharmacological analysis **2517**

**M. Burnier, G. Centeno, G. Waeber, C. Centeno & E. Bürki.** Effect of endotoxin on the angiotensin II receptor in cultured vascular smooth muscle cells **2524**

**Y. Noda, K. Yamada, H. Furukawa & T. Nabeshima.** Enhancement of immobility in a forced swimming test by subacute or repeated treatment with phencyclidine: a new model of schizophrenia **2531**

**E.C.M. de Lange, M.R. Bouw, J.W. Mandema, M. Danhof, A.G. de Boer & D.D. Breimer.** Application of intracerebral microdialysis to study regional distribution kinetics of drugs in rat brain **2538**

The *British Journal of Pharmacology* is published by Stockton Press, a division of Macmillan Press Ltd. It is the official publication of the British Pharmacological Society.

**Scope** The *British Journal of Pharmacology* is published twice a month. It welcomes contribution in all fields of experimental pharmacology including neuroscience, biochemical, cellular and molecular pharmacology. The Board of Editors represents a wide range of expertise and ensures that well-presented work is published as promptly as possible, consistent with maintaining the overall quality of the journal.

This journal is covered by Current Contents, Excerpta Medica, BIOSIS, CABS, CINAHL and Index Medicus.

**Editorial** Manuscripts (plus two copies) and all editorial correspondence should be sent to: The Editorial Office, British Journal of Pharmacology, St George's Hospital Medical School, Cranmer Terrace, London SW17 0RE, UK. Tel: +44 (0)181 767 6765; Fax: +44 (0)181 767 5645.

**Advertisements** Enquiries concerning advertisements should be addressed to: Michael Rowley, Hasler House, High Street, Great Dunmow, Essex CM6 1AP, UK. Tel: +44 (0)1371 874613; Fax: +44 (0)1371 872273.

**Publisher** All business correspondence, supplement enquiries and reprint requests should be addressed to British Journal of Pharmacology, Stockton Press, Houndmills, Basingstoke, Hampshire RG21 2XS, UK. Tel: +44 (0)1256 29242; Fax: +44 (0)1256 810526. Publisher: Marija Vukovojac. Production Controller: Nicci Crawley.

**Subscriptions – EU/Rest of World** Subscription price per annum (3 volumes, 24 issues) £620, rest of world £820 (Airmail), £685 (Surface mail) or equivalent in any other currency. Orders must be accompanied by remittance. Cheques should be made payable to Macmillan Magazines and sent to: The Subscription Department Macmillan Press Ltd, Houndmills, Basingstoke, Hampshire RG21 2XS, UK. Where appropriate, subscribers may make payments into UK Post Office Giro Account No. 519 2455. Full details must accompany the payment. Subscribers from EC territories should add sales tax at the local rate.

**Subscriptions – USA** USA subscribers call toll free 1-800-221-2123 or send check/money order/credit card details to: Stockton Press, 49, West 24th Street, New York, NY 10010; Tel: 212 627 5757, Fax: 212 627 9256. USA annual subscription rates: \$1230 Airmail; \$1030 Surface (Institutional/Corporate); \$225 (Individual making personal payment).

*British Journal of Pharmacology* (ISSN 0007-1188) is published twice a month by Macmillan Press Ltd, c/o Mercury Airfreight International Ltd, 2323 Randolph Avenue, Avenel, NJ 07001, USA. Subscription price for institutions is \$1030 per annum (surface). 2nd class postage is paid at Rahway NJ. Postmaster: send address corrections to Macmillan Press Ltd, c/o Mercury Airfreight International Ltd, 2323 Randolph Avenue, Avenel NJ 07001.

**Reprints** of any article in this journal are available from Stockton Press, Houndmills, Basingstoke, Hampshire RG21 2XS, UK. Tel: +44 (0)1256 29242; Fax: +44 (0)1256 810526.

**Copyright** © 1995 Stockton Press  
ISSN 0007-1188

All rights of reproduction are reserved in respect of all papers, articles, illustrations, etc., published in this journal in all countries of the world.

All material published in this journal is protected by copyright, which covers exclusive rights to reproduce and distribute the material. No material published in this journal may be reproduced or stored on microfilm or in electronic, optical or magnetic form without the written authorisation of the Publisher.

Authorisation to photocopy items for internal or personal use of specific clients, is granted by Stockton Press for libraries and other users registered with the Copyright Clearance Center (CCC) Transaction Reporting Service, provided that the base fee of \$12.00 per copy is paid directly to CCC, 21 Congress St., Salem, MA 01970, USA. 0007-1188/95 \$12.00 + \$0.00.

Apart from any fair dealing for the purposes of research or private study, or criticism or review, as permitted under the Copyright, Designs and Patent Act 1988, this publication may be reproduced, stored or transmitted, in any form or by any means, only with the prior permission in writing of the publishers, or in the case of reprographic reproduction, in accordance with the terms of licences issued by the Copyright Licensing Agency.

## PREPARATION OF MANUSCRIPTS

Authors are strongly recommended to read the full *Instructions to Authors and Nomenclature Guidelines for Authors* (Br. J. Pharmacol. 1995, **114**, 245–255) before submitting a manuscript for publication in the *British Journal of Pharmacology*. The manuscript and cover letter should be checked against the following list before mailing.

The original and one copy of the manuscript must be supplied. Manuscripts must be typed in double-line spacing on one side of A4 paper, in type not smaller than 12 characters per inch or 10 point. Both copies to include Tables and a set of labelled Figures. One set of Figures without numbers or letters is also to be included. The text to be arranged in the following subsections:

1. **Title**—To have no more than 150 characters on a separate page, which should also include a Short Title (50 characters maximum) and the name and address of the author for correspondence.
2. **Summary**—To be arranged in numbered paragraphs (Full Papers) or a single paragraph (Special Reports).  
—to include aims, principal results and conclusions.  
—to include Key words (10 maximum) at end of summary.
3. **Introduction**—To contain concise statements of the problem and the aims of the investigation.
4. **Methods**—To have brief but adequate account of the procedures; *full names of drugs (including those referred to by manufacturer's code)*, sources of drugs and statistical tests to be stated.
5. **Results**—To have no repetition of data in Figures, Tables and text.
6. **Discussion**—Findings and conclusions to be placed in context of other relevant work.  
*NB* Simple repetition of results and unwarranted speculation are not acceptable.
7. **Acknowledgements**—Sources of support. Sources of drugs not widely available commercially.
8. **References**—All references in the text to be included in the Reference List and *vice versa*. References in alphabetical order with complete citations; Journals publishing 'in press' papers identified.

*References to manuscripts submitted to other journals but not yet accepted are not allowed.*

9. **Tables**—Each on a separate page and prepared in accordance with current requirements of the Journal.
10. **Figures**—Both labelled and non-labelled Figures to be prepared in accordance with current requirements of the Journal (see *Instructions to Authors*, 1994, **114**, 245–251) and provided with Figure Number and Authors' names on back (*in pencil*).  
—each legend to be typed on a separate page and carrying keys to symbols.  
—keys to symbols and histograms must not appear on the figures themselves, but in the respective legends.  
—'box style' figures are not in keeping with the Journal style; line drawings etc must have only left-hand and bottom axes.
11. **Manuscripts**—To be accompanied by a declaration signed by each author that
  - (a) results are original
  - (b) approval of all persons concerned has been given to submit manuscripts for consideration (see also 12b)
  - (c) the same material is neither 'in press' (i.e. is in proof or has definitely been accepted for publication) nor under consideration elsewhere. Furthermore it will not be submitted or published elsewhere before a decision has been reached by the Editorial Board of the *British Journal of Pharmacology* and will not be submitted elsewhere if accepted by the *British Journal of Pharmacology*.
  - (d) Copyright assignment is included.
12. **Cover letter**—To state clearly
  - (a) Corresponding author's full postal address, telephone, telex or Fax number
  - (b) where appropriate, that *either* ethical approval has been given for investigation or Company or Institutional permission to publish work has been received.
13. **Reminder**—Packaging to be sufficiently robust to protect Figures and to withstand mailing.

Failure to comply with *Instructions to Authors* may lead to substantial delays in processing, review and publication and may even jeopardize acceptance of the manuscript.

## NOMENCLATURE

Authors are reminded that accepted receptor and associated terminology is laid out in *Nomenclature Guidelines for Authors*, as published in the *British Journal of Pharmacology*, Br. J. Pharmacol., 1995, **114**, 253–255.

## SPECIAL REPORTS

The purpose of *Special Reports* is to provide rapid publication for **new** and **important** results which the Editorial Board considers are likely to be of special pharmacological significance. *Special Reports* will have publication priority over all other material and so authors are asked to consider carefully the status of their work before submission.

In order to speed publication there is normally no revision allowed beyond very minor typographical or grammatical corrections. If significant revision is required, the Board may either invite rapid re-submission or, more probably, propose that it be re-written as a Full Paper and be re-submitted for consideration. In order to reduce delays, proofs of *Special Reports* will be sent to authors but **essential corrections must reach the Production Office within 48 hours of receipt**. Authors should ensure that their submitted material conforms exactly to the following requirements.

*Special Reports* should normally occupy no more than two printed pages of the Journal; two illustrations (Figures or Tables, with legends) are permitted. As a guideline, with type face of 12 pitch and double-line spacing, a page of A4 paper could contain about 400 words. The absolute maximum length of the *Special Report* is 1700 words. For each Figure or Table, please deduct 200 words. The manuscript should comprise a Title page with key words (maximum of 10), a Summary consisting of a single short paragraph, followed by Introduction, Methods, Results, Discussion and References (maximum of 10). In all other respects, the requirements are the same as for Full Papers (see current 'Instructions to Authors').

## SPECIAL REPORTS

S. Boehm, S. Huck & P. Illes. UTP- and ATP-triggered transmitter release from rat sympathetic neurones via separate receptors 2341

I. Margail, M. Allix, C. Charriaut-Marlangue, R.G. Boulu & M. Plotkine. Loss of NADPH-diaphorase containing neurones after reversible focal ischaemia in rats delayed by L-NAME 2344

N.A. Brown, G. McAllister, D. Weinberg, G. Milligan & G.R. Seabrook. Involvement of G-protein  $\alpha$ l subunits in activation of G-protein gated inward rectifying K<sup>+</sup> channels (GIRK1) by human NPY<sub>1</sub> receptors 2346

R.L.C. Handy, P. Wallace, Z.A. Gaffen, K.J. Whitehead & P.K. Moore. The antinociceptive effect of 1-(2-trifluoromethylphenyl) imidazole (TRIM), a potent inhibitor of neuronal nitric oxide synthase *in vitro*, in the mouse 2349

## PAPERS

C.A. Lewis & K.J. Broadley. Airway hyper- or hyporeactivity to inhaled spasmogens 24 h after ovalbumin challenge of sensitized guinea-pigs 2351

R.Y.K. Man & A.A.A. Kinnaird. Similar coronary vascular effects in the rat perfused heart of platelet-activating factor structural analogues with agonist and antagonist properties 2359

P. Holzer, M. Jocić & B.A. Peskar. Mediation by prostaglandins of the nitric-oxide-induced neurogenic vasodilatation in rat skin 2365

I.S. Ebenezer & B.A. Baldwin. 2-Naphthalenesulphonyl-L-aspartyl-2-(phenethyl) amide (2-NAP) and food intake in rats: evidence that endogenous peripheral CCK does not play a major role as a satiety factor 2371

R.R. Brett & J.A. Pratt. Changes in benzodiazepine-GABA receptor coupling in an accumbens-habenula circuit after chronic diazepam treatment 2375

P. Gupta, D. Brown, P. Butler, P. Ellis, K.L. Grayson, G.C. Land, J.E. Macor, S.F. Robson, M.J. Wythes & N.B. Shepperson. The *in vivo* pharmacological profile of a 5-HT<sub>1</sub> receptor agonist, CP-122,288, a selective inhibitor of neurogenic inflammation 2385

A. de Cupis, D. Noonan, P. Pirani, A. Ferrera, L. Clerico & R.E. Favoni. Comparison between novel steroid-like and conventional nonsteroidal oestrogens in inhibiting oestradiol- and IGF-I-induced proliferation of human breast cancer-derived cells 2391

S. Palea, M. Corsi, J.M. Rimland, D.G. Trist & E. Ratti. Failure of the putative neuropeptide Y antagonists, benextramine and PYX-2, to inhibit Y<sub>2</sub> receptors in rat isolated prostatic vas deferens 2401

J. Vergés, L. Héroux, H. Maurice & P. du Souich. Extrahepatic metabolism of frusemide in anaesthetized rabbits 2407

C. Brown, B. Tanna & M.R. Boarder. PPADS: an antagonist at endothelial P<sub>2Y</sub>-purinoceptors but not P<sub>2U</sub>-purinoceptors 2413

H.S. Chowdrey, P.J. Larsen, M.S. Harbuz, D.S. Jessop, G. Aguilera, D.J.A. Eckland & S.L. Lightman. Evidence for arginine vasopressin as the primary activator of the HPA axis during adjuvant-induced arthritis 2417

A. Losinski & S.P.H. Alexander. Adenosine receptor-mediated relaxation of guinea-pig precontracted, isolated trachea 2425

M.R. Panara, A. Greco, G. Santini, M.G. Sciulli, M.T. Rotondo, R. Padovano, M. di Giamberardino, F. Cipollone, F. Cuccurullo, C. Patrono & P. Patrignani. Effects of the novel anti-inflammatory compounds, N-[2-(cyclohexyloxy)-4-nitrophenyl] methanesulphonamide (NS-398) and 5-methanesulphonamido-6-(2,4-difluorothiophenyl)-1-indanone (L-745,337), on the cyclo-oxygenase activity of human blood prosta-glandin endoperoxide synthases 2429

E.J. Hide, P. Ney, J. Piper, C. Thiemermann & J.R. Vane. Reduction by prostaglandin E<sub>1</sub> or prostaglandin E<sub>0</sub> of myocardial infarct size in the rabbit by activation of ATP-sensitive potassium channels 2435

J.C.M. Yu, J.D. Pickard & A.P. Davenport. Endothelin ET<sub>A</sub> receptor expression in human cerebrovascular smooth muscle cells 2441

Z-Y. Wang & R. Håkanson. Role of nitric oxide (NO) in ocular inflammation 2447

K.D. Thornbury, K.M. Donaghy & J. Peake. Characteristics of the NANC post-stimulus ('rebound') contraction of the urinary bladder neck muscle in sheep 2451

B.K. Kemp, J.J. Smolich, B.C. Ritchie & T.M. Cocks. Endothelium-dependent relaxations in sheep pulmonary arteries and veins: resistance to block by N<sup>G</sup>-nitro-L-arginine in pulmonary hypertension 2457

L. Tang, C.P. Smith, F.P. Huger & S. Kongsamut. Effects of besipirdine at the voltage-dependent sodium channel 2468

G.R. Drummond & T.M. Cocks. Endothelium-dependent relaxations mediated by inducible B<sub>1</sub> and constitutive B<sub>2</sub> kinin receptors in the bovine isolated coronary artery 2473

G.H. Allcock, T.D. Warner & J.R. Vane. Roles of endothelin receptors in the regional and systemic vascular responses to ET-1 in the anaesthetized ganglion-blocked rat: use of selective antagonists 2482

J. Waller, S.M. Gardiner, J. Jose & T. Bennett. Lack of effect of TNF antibodies on the cardiovascular sequelae of lipopolysaccharide infusion in conscious rats 2487

O. Piot, J. Betschart, I. Grall, S. Ravard, C. Garret & J.-C. Blanchard. Comparative behavioural profile of centrally administered tachykinin NK<sub>1</sub>, NK<sub>2</sub> and NK<sub>3</sub> receptor agonists in the guinea-pig 2496

H. El-Bizri, M.G. Rigdon & P.B.S. Clarke. Intraneuronal accumulation and persistence of radiolabel in rat brain following *in vivo* administration of [<sup>3</sup>H]-chlorisondamine 2503

K.E. Ellis, R. Mistry, J.P. Boyle & R.A. J. Challiss. Correlation of cyclic AMP accumulation and relaxant actions of salmeterol and salbutamol in bovine tracheal smooth muscle 2510

M. Takeda & H. Lepor. Nitric oxide synthase in dog urethra: a histochemical and pharmacological analysis 2517

M. Burnier, G. Centeno, G. Waeber, C. Centeno & E. Bürki. Effect of endotoxin on the angiotensin II receptor in cultured vascular smooth muscle cells 2524

Y. Noda, K. Yamada, H. Furukawa & T. Nabeshima. Enhancement of immobility in a forced swimming test by subacute or repeated treatment with phencyclidine: a new model of schizophrenia 2531

E.C.M. de Lange, M.R. Bouw, J.W. Mandema, M. Danhof, A.G. de Boer & D.D. Breimer. Application of intracerebral microdialysis to study regional distribution kinetics of drugs in rat brain 2538